Back
ESC Professional Premium Access

Omecamtiv mecarbil for the management of heart failure: a meta-analysis of randomized controlled trials

Session: Heart failure pharmacology
Topic: Pharmacotherapy
Speaker: Doctor V. Hurtado (Miami, US)
Event: ESC Congress 2022

Congress Presentation

Add to my library

Like

About the speaker

Doctor Vanessa Hurtado

University of Miami Hospital, Miami (United States of America)
1 follower

6 more presentations in this session

Adherence and discontinuation of optimal heart failure therapies according to age

Speaker: Miss C. Garred (Gentofte, DK)

Access
Abstract
Slides
Like
Thumbnail

Maximally tolerated guideline-directed medical therapy and barriers to optimization in patients with heart failure with reduced ejection fraction: The COAPT trial

Speaker: Associate Professor Z. Cox (Nashville, US)

Access
Abstract
Slides
Like
Thumbnail

Real-world eligibility for vericiguat according to trial, guideline, and labelling eligibility criteria: data from the Swedish Heart Failure Registry

Speaker: Mr V. Nguyen (Stockholm, SE)

Access
Abstract
Slides
Like
Thumbnail

Efficacy of sodium glucose cotransporter 2 inhibitors for heart failure with preserved and mildly reduced ejection fraction: a systematic review and meta-analysis

Speaker: Doctor K. Rivera (Manila, PH)

Access
Abstract
Slides
Like
Thumbnail

Compliance to guideline-recommended pharmacotherapy in patients with heart failure, 2014 to 2020

Speaker: Doctor K. Odegaard (Oslo, NO)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Heart failure pharmacology

Speakers: Doctor V. Hurtado, Miss C. Garred, Associate Professor Z. Cox, Mr V. Nguyen, Doctor K. Rivera...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources